Predictors Of Mortality After Pelvic Fractures: A Retrospective Cohort Study From A Level-1 Trauma Center In Upper Egypt

Predictors Of Mortality After Pelvic Fractures: A Retrospective Cohort Study From A Level-1 Trauma Center In Upper Egypt.

A retrospective cohort study was carried out for all pelvic fracture patients admitted to Assiut University Trauma Unit (AUTU), a level-1 trauma center. (AUTU) is located in Upper Egypt and provides healthcare to over 30,000 patients per year.

Study Overview

• Status: Completed
• Conditions: Morality; Registries; Pelvic Bone Injury
• Intervention / Treatment: Other: The presence of a pelvic fracture

Detailed Description

In 2010, a Pelvic Injury Registry was developed to document treatment and outcomes in a standardized manner. All patients admitted to AUTU sign an informed consent to permit using their data for research purposes. Patients' data are prospectively collected and stored in a local database specifically designed for this purpose.

Data collected included age, gender, mechanism of injury, fracture classification, associated injuries, and admission to ICU, the length of hospital stay and presence of abdominopelvic collection as diagnosed by Focused Assessment with Sonography for Trauma (FAST) at admission. The primary outcome measure was in-hospital mortality. Predictors of in-hospital mortality were identified by comparing characters of survivors and non-survivors. Secondary objectives were to analyse the differences between adults and children and to analyse the causes and timing of death.

• Study Type: Observational
• Enrollment (Actual): 1188

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

1188 patients were considered eligible for analysis. These were further divided into an adult cohort whose age is above 16 years (951 patients) and a pediatric cohort (237 patients).

Description

Inclusion Criteria:

• first-time admissions and patients whose treatment was completed at our hospital
• all pelvic fracture patients admitted to our Trauma Unit.

Exclusion Criteria:

• penetrating injuries
• isolated acetabular fractures
• Patients who were discharged on their own will against the medical advice or whose treatment was continued at another hospital
• re-admitted patients
• Firearm injuries

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Survivors; Patients whose pelvic fracture and survived till time of discharge from the hospital.	Other: The presence of a pelvic fracture
Non-Survivors; Patients whose pelvic fracture and died while in hospital.	Other: The presence of a pelvic fracture

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
in-hospital mortality	Death occurring while the patient is admitted in the hospital.	One month

Collaborators and Investigators

• Sponsor: Assiut University
• Collaborators: AO Clinical Investigation and Publishing Documentation
• Investigators: Principal Investigator: Osama Farouk, Assiut University

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2010
• Primary Completion (Actual): December 31, 2013
• Study Completion (Actual): September 1, 2017

Study Registration Dates

• First Submitted: July 5, 2018
• First Submitted That Met QC Criteria: August 5, 2018
• First Posted (Actual): August 7, 2018

Study Record Updates

• Last Update Posted (Actual): February 16, 2022
• Last Update Submitted That Met QC Criteria: February 15, 2022
• Last Verified: February 1, 2022

More Information

Terms related to this study

• Keywords: predictors; mortality; Pelvic fractures; trauma registry
• Additional Relevant MeSH Terms: Fractures, Bone; Wounds and Injuries; Leg Injuries; Femoral Fractures; Hip Injuries; Hip Fractures
• Other Study ID Numbers: 17100526

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No